nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—Monobenzone—TYR—skin cancer	0.0371	0.863	CrCbGaD
Dextroamphetamine—Cardiomyopathy—Imiquimod—skin cancer	0.0225	0.0263	CcSEcCtD
Dextroamphetamine—Tooth disorder—Imiquimod—skin cancer	0.0178	0.0208	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Vismodegib—skin cancer	0.0145	0.0169	CcSEcCtD
Dextroamphetamine—Viral infection—Imiquimod—skin cancer	0.0128	0.0149	CcSEcCtD
Dextroamphetamine—Cardiomyopathy—Fluorouracil—skin cancer	0.0124	0.0145	CcSEcCtD
Dextroamphetamine—Sudden death—Fluorouracil—skin cancer	0.0124	0.0145	CcSEcCtD
Dextroamphetamine—Weight decreased—Vismodegib—skin cancer	0.0124	0.0145	CcSEcCtD
Dextroamphetamine—TAAR1—neck—skin cancer	0.0115	0.272	CbGeAlD
Dextroamphetamine—Tooth disorder—Temozolomide—skin cancer	0.0107	0.0124	CcSEcCtD
Dextroamphetamine—Digestion impaired—Temozolomide—skin cancer	0.0103	0.0121	CcSEcCtD
Dextroamphetamine—Injury—Imiquimod—skin cancer	0.00911	0.0106	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Vemurafenib—skin cancer	0.00884	0.0103	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Imiquimod—skin cancer	0.00854	0.00998	CcSEcCtD
Dextroamphetamine—Speech disorder—Temozolomide—skin cancer	0.00804	0.00938	CcSEcCtD
Dextroamphetamine—Irritability—Imiquimod—skin cancer	0.00799	0.00933	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Vemurafenib—skin cancer	0.00774	0.00904	CcSEcCtD
Dextroamphetamine—Weight decreased—Vemurafenib—skin cancer	0.00768	0.00896	CcSEcCtD
Dextroamphetamine—Viral infection—Temozolomide—skin cancer	0.00765	0.00894	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Vemurafenib—skin cancer	0.0075	0.00876	CcSEcCtD
Dextroamphetamine—Speech disorder—Fluorouracil—skin cancer	0.0074	0.00865	CcSEcCtD
Dextroamphetamine—Dyspepsia—Vismodegib—skin cancer	0.00687	0.00803	CcSEcCtD
Dextroamphetamine—Decreased appetite—Vismodegib—skin cancer	0.00679	0.00793	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Vismodegib—skin cancer	0.00674	0.00787	CcSEcCtD
Dextroamphetamine—Fatigue—Vismodegib—skin cancer	0.00673	0.00786	CcSEcCtD
Dextroamphetamine—Constipation—Vismodegib—skin cancer	0.00668	0.0078	CcSEcCtD
Dextroamphetamine—Erectile dysfunction—Imiquimod—skin cancer	0.00666	0.00778	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Imiquimod—skin cancer	0.0066	0.00771	CcSEcCtD
Dextroamphetamine—Injury—Bleomycin—skin cancer	0.00647	0.00756	CcSEcCtD
Dextroamphetamine—Depression—Imiquimod—skin cancer	0.00643	0.00751	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Vemurafenib—skin cancer	0.00642	0.0075	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.0064	0.00747	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Vismodegib—skin cancer	0.00639	0.00746	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Imiquimod—skin cancer	0.00636	0.00743	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Imiquimod—skin cancer	0.00632	0.00738	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Imiquimod—skin cancer	0.00627	0.00732	CcSEcCtD
Dextroamphetamine—Abdominal pain—Vismodegib—skin cancer	0.00617	0.00721	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Bleomycin—skin cancer	0.00607	0.00709	CcSEcCtD
Dextroamphetamine—Lacosamide—SCN10A—skin cancer	0.00588	0.137	CrCbGaD
Dextroamphetamine—TAAR1—female reproductive system—skin cancer	0.0058	0.138	CbGeAlD
Dextroamphetamine—Asthenia—Vismodegib—skin cancer	0.0056	0.00654	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Imiquimod—skin cancer	0.00548	0.00639	CcSEcCtD
Dextroamphetamine—Euphoric mood—Fluorouracil—skin cancer	0.00547	0.00639	CcSEcCtD
Dextroamphetamine—Diarrhoea—Vismodegib—skin cancer	0.00534	0.00624	CcSEcCtD
Dextroamphetamine—SLC6A3—nerve—skin cancer	0.00525	0.125	CbGeAlD
Dextroamphetamine—SLC18A2—Synaptic Vesicle Pathway—SYP—skin cancer	0.0051	0.0872	CbGpPWpGaD
Dextroamphetamine—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.005	0.00583	CcSEcCtD
Dextroamphetamine—Vomiting—Vismodegib—skin cancer	0.00497	0.0058	CcSEcCtD
Dextroamphetamine—Affect lability—Temozolomide—skin cancer	0.00494	0.00577	CcSEcCtD
Dextroamphetamine—Rash—Vismodegib—skin cancer	0.00492	0.00575	CcSEcCtD
Dextroamphetamine—Dermatitis—Vismodegib—skin cancer	0.00492	0.00574	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Vemurafenib—skin cancer	0.00482	0.00563	CcSEcCtD
Dextroamphetamine—Infection—Vemurafenib—skin cancer	0.00479	0.0056	CcSEcCtD
Dextroamphetamine—Mood swings—Temozolomide—skin cancer	0.00475	0.00555	CcSEcCtD
Dextroamphetamine—Weight decreased—Bleomycin—skin cancer	0.00465	0.00543	CcSEcCtD
Dextroamphetamine—Nausea—Vismodegib—skin cancer	0.00464	0.00542	CcSEcCtD
Dextroamphetamine—Agitation—Imiquimod—skin cancer	0.00463	0.00541	CcSEcCtD
Dextroamphetamine—Angioedema—Imiquimod—skin cancer	0.00461	0.00538	CcSEcCtD
Dextroamphetamine—Blood pressure increased—Docetaxel—skin cancer	0.0046	0.00537	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Bleomycin—skin cancer	0.00452	0.00528	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.00452	0.00528	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Bleomycin—skin cancer	0.00449	0.00525	CcSEcCtD
Dextroamphetamine—SLC18A2—Dopaminergic Neurogenesis—GLI2—skin cancer	0.00448	0.0766	CbGpPWpGaD
Dextroamphetamine—Palpitations—Imiquimod—skin cancer	0.00446	0.0052	CcSEcCtD
Dextroamphetamine—Irritability—Fluorouracil—skin cancer	0.00441	0.00515	CcSEcCtD
Dextroamphetamine—Convulsion—Imiquimod—skin cancer	0.00437	0.0051	CcSEcCtD
Dextroamphetamine—Hypertension—Imiquimod—skin cancer	0.00435	0.00508	CcSEcCtD
Dextroamphetamine—Chest pain—Imiquimod—skin cancer	0.00429	0.00501	CcSEcCtD
Dextroamphetamine—Anxiety—Imiquimod—skin cancer	0.00428	0.005	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.00424	0.00495	CcSEcCtD
Dextroamphetamine—SLC6A2—nerve—skin cancer	0.00424	0.1	CbGeAlD
Dextroamphetamine—SLC18A2—Dopaminergic Neurogenesis—GLI1—skin cancer	0.00421	0.072	CbGpPWpGaD
Dextroamphetamine—Dry mouth—Imiquimod—skin cancer	0.0042	0.0049	CcSEcCtD
Dextroamphetamine—Decreased appetite—Vemurafenib—skin cancer	0.00419	0.0049	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00417	0.00486	CcSEcCtD
Dextroamphetamine—Fatigue—Vemurafenib—skin cancer	0.00416	0.00486	CcSEcCtD
Dextroamphetamine—Constipation—Vemurafenib—skin cancer	0.00413	0.00482	CcSEcCtD
Dextroamphetamine—Lightheadedness—Docetaxel—skin cancer	0.00411	0.0048	CcSEcCtD
Dextroamphetamine—Infection—Imiquimod—skin cancer	0.00409	0.00477	CcSEcCtD
Dextroamphetamine—Tachycardia—Imiquimod—skin cancer	0.00402	0.00469	CcSEcCtD
Dextroamphetamine—Erectile dysfunction—Temozolomide—skin cancer	0.00399	0.00466	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Imiquimod—skin cancer	0.00398	0.00465	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Temozolomide—skin cancer	0.00396	0.00462	CcSEcCtD
Dextroamphetamine—Weight decreased—Temozolomide—skin cancer	0.00392	0.00458	CcSEcCtD
Dextroamphetamine—Anorexia—Imiquimod—skin cancer	0.00392	0.00458	CcSEcCtD
Dextroamphetamine—Depression—Temozolomide—skin cancer	0.00386	0.0045	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.00383	0.00448	CcSEcCtD
Dextroamphetamine—Body temperature increased—Vemurafenib—skin cancer	0.00381	0.00445	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Temozolomide—skin cancer	0.00376	0.00439	CcSEcCtD
Dextroamphetamine—Insomnia—Imiquimod—skin cancer	0.00372	0.00435	CcSEcCtD
Dextroamphetamine—Dyspnoea—Imiquimod—skin cancer	0.00367	0.00428	CcSEcCtD
Dextroamphetamine—Somnolence—Imiquimod—skin cancer	0.00366	0.00427	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Fluorouracil—skin cancer	0.00365	0.00426	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Dactinomycin—skin cancer	0.00363	0.00424	CcSEcCtD
Dextroamphetamine—Dyspepsia—Imiquimod—skin cancer	0.00362	0.00423	CcSEcCtD
Dextroamphetamine—Decreased appetite—Imiquimod—skin cancer	0.00358	0.00418	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Vemurafenib—skin cancer	0.00355	0.00415	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Imiquimod—skin cancer	0.00355	0.00415	CcSEcCtD
Dextroamphetamine—Fatigue—Imiquimod—skin cancer	0.00355	0.00414	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Fluorouracil—skin cancer	0.00351	0.0041	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Fluorouracil—skin cancer	0.00349	0.00408	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Fluorouracil—skin cancer	0.00346	0.00404	CcSEcCtD
Dextroamphetamine—Asthenia—Vemurafenib—skin cancer	0.00346	0.00404	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Imiquimod—skin cancer	0.00336	0.00393	CcSEcCtD
Dextroamphetamine—Diarrhoea—Vemurafenib—skin cancer	0.0033	0.00386	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Temozolomide—skin cancer	0.00328	0.00383	CcSEcCtD
Dextroamphetamine—Urticaria—Imiquimod—skin cancer	0.00327	0.00382	CcSEcCtD
Dextroamphetamine—Body temperature increased—Imiquimod—skin cancer	0.00325	0.0038	CcSEcCtD
Dextroamphetamine—Abdominal pain—Imiquimod—skin cancer	0.00325	0.0038	CcSEcCtD
Dextroamphetamine—Dizziness—Vemurafenib—skin cancer	0.00319	0.00373	CcSEcCtD
Dextroamphetamine—Vomiting—Vemurafenib—skin cancer	0.00307	0.00358	CcSEcCtD
Dextroamphetamine—Chest pain—Bleomycin—skin cancer	0.00305	0.00356	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Docetaxel—skin cancer	0.00305	0.00356	CcSEcCtD
Dextroamphetamine—SLC18A2—Dopaminergic Neurogenesis—SHH—skin cancer	0.00304	0.052	CbGpPWpGaD
Dextroamphetamine—Rash—Vemurafenib—skin cancer	0.00304	0.00355	CcSEcCtD
Dextroamphetamine—Dermatitis—Vemurafenib—skin cancer	0.00304	0.00355	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Imiquimod—skin cancer	0.00303	0.00354	CcSEcCtD
Dextroamphetamine—Headache—Vemurafenib—skin cancer	0.00302	0.00353	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.003	0.00351	CcSEcCtD
Dextroamphetamine—Asthenia—Imiquimod—skin cancer	0.00295	0.00345	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Bleomycin—skin cancer	0.00292	0.00341	CcSEcCtD
Dextroamphetamine—Infection—Bleomycin—skin cancer	0.0029	0.00339	CcSEcCtD
Dextroamphetamine—Nausea—Vemurafenib—skin cancer	0.00287	0.00335	CcSEcCtD
Dextroamphetamine—Tremor—Temozolomide—skin cancer	0.00283	0.00331	CcSEcCtD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—MC1R—skin cancer	0.00282	0.0482	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Imiquimod—skin cancer	0.00282	0.00329	CcSEcCtD
Dextroamphetamine—Anorexia—Bleomycin—skin cancer	0.00279	0.00325	CcSEcCtD
Dextroamphetamine—Agitation—Temozolomide—skin cancer	0.00278	0.00324	CcSEcCtD
Dextroamphetamine—Angioedema—Temozolomide—skin cancer	0.00276	0.00322	CcSEcCtD
Dextroamphetamine—Dizziness—Imiquimod—skin cancer	0.00272	0.00318	CcSEcCtD
Dextroamphetamine—Infection—Dactinomycin—skin cancer	0.00271	0.00316	CcSEcCtD
Dextroamphetamine—Palpitations—Temozolomide—skin cancer	0.00267	0.00312	CcSEcCtD
Dextroamphetamine—SLC6A3—Dopaminergic Neurogenesis—GLI2—skin cancer	0.00267	0.0456	CbGpPWpGaD
Dextroamphetamine—Convulsion—Temozolomide—skin cancer	0.00262	0.00306	CcSEcCtD
Dextroamphetamine—Vomiting—Imiquimod—skin cancer	0.00262	0.00306	CcSEcCtD
Dextroamphetamine—Weight decreased—Docetaxel—skin cancer	0.00261	0.00305	CcSEcCtD
Dextroamphetamine—Hypertension—Temozolomide—skin cancer	0.00261	0.00305	CcSEcCtD
Dextroamphetamine—Dyspnoea—Bleomycin—skin cancer	0.00261	0.00304	CcSEcCtD
Dextroamphetamine—Anorexia—Dactinomycin—skin cancer	0.0026	0.00303	CcSEcCtD
Dextroamphetamine—Rash—Imiquimod—skin cancer	0.00259	0.00303	CcSEcCtD
Dextroamphetamine—Dermatitis—Imiquimod—skin cancer	0.00259	0.00303	CcSEcCtD
Dextroamphetamine—Headache—Imiquimod—skin cancer	0.00258	0.00301	CcSEcCtD
Dextroamphetamine—Anxiety—Temozolomide—skin cancer	0.00256	0.00299	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.00255	0.00298	CcSEcCtD
Dextroamphetamine—Decreased appetite—Bleomycin—skin cancer	0.00254	0.00297	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Docetaxel—skin cancer	0.00253	0.00296	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Docetaxel—skin cancer	0.00252	0.00294	CcSEcCtD
Dextroamphetamine—Dry mouth—Temozolomide—skin cancer	0.00252	0.00294	CcSEcCtD
Dextroamphetamine—SLC6A3—Dopaminergic Neurogenesis—GLI1—skin cancer	0.00251	0.0429	CbGpPWpGaD
Dextroamphetamine—Anaphylactic shock—Temozolomide—skin cancer	0.00247	0.00288	CcSEcCtD
Dextroamphetamine—Infection—Temozolomide—skin cancer	0.00245	0.00286	CcSEcCtD
Dextroamphetamine—Nausea—Imiquimod—skin cancer	0.00244	0.00285	CcSEcCtD
Dextroamphetamine—Convulsion—Fluorouracil—skin cancer	0.00241	0.00282	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Temozolomide—skin cancer	0.00238	0.00278	CcSEcCtD
Dextroamphetamine—Chest pain—Fluorouracil—skin cancer	0.00237	0.00277	CcSEcCtD
Dextroamphetamine—Decreased appetite—Dactinomycin—skin cancer	0.00237	0.00277	CcSEcCtD
Dextroamphetamine—Fatigue—Dactinomycin—skin cancer	0.00235	0.00274	CcSEcCtD
Dextroamphetamine—Anorexia—Temozolomide—skin cancer	0.00235	0.00274	CcSEcCtD
Dextroamphetamine—Urticaria—Bleomycin—skin cancer	0.00232	0.00271	CcSEcCtD
Dextroamphetamine—Body temperature increased—Bleomycin—skin cancer	0.00231	0.0027	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Fluorouracil—skin cancer	0.00227	0.00265	CcSEcCtD
Dextroamphetamine—Infection—Fluorouracil—skin cancer	0.00226	0.00264	CcSEcCtD
Dextroamphetamine—Insomnia—Temozolomide—skin cancer	0.00223	0.0026	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Dactinomycin—skin cancer	0.00223	0.0026	CcSEcCtD
Dextroamphetamine—Tachycardia—Fluorouracil—skin cancer	0.00222	0.00259	CcSEcCtD
Dextroamphetamine—Dyspnoea—Temozolomide—skin cancer	0.0022	0.00257	CcSEcCtD
Dextroamphetamine—Somnolence—Temozolomide—skin cancer	0.00219	0.00256	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Docetaxel—skin cancer	0.00218	0.00255	CcSEcCtD
Dextroamphetamine—Dyspepsia—Temozolomide—skin cancer	0.00217	0.00253	CcSEcCtD
Dextroamphetamine—Anorexia—Fluorouracil—skin cancer	0.00217	0.00253	CcSEcCtD
Dextroamphetamine—Body temperature increased—Dactinomycin—skin cancer	0.00216	0.00252	CcSEcCtD
Dextroamphetamine—Abdominal pain—Dactinomycin—skin cancer	0.00216	0.00252	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Bleomycin—skin cancer	0.00215	0.00251	CcSEcCtD
Dextroamphetamine—Decreased appetite—Temozolomide—skin cancer	0.00214	0.0025	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Temozolomide—skin cancer	0.00213	0.00249	CcSEcCtD
Dextroamphetamine—Fatigue—Temozolomide—skin cancer	0.00213	0.00248	CcSEcCtD
Dextroamphetamine—Constipation—Temozolomide—skin cancer	0.00211	0.00246	CcSEcCtD
Dextroamphetamine—Asthenia—Bleomycin—skin cancer	0.0021	0.00245	CcSEcCtD
Dextroamphetamine—Insomnia—Fluorouracil—skin cancer	0.00205	0.0024	CcSEcCtD
Dextroamphetamine—Dyspnoea—Fluorouracil—skin cancer	0.00203	0.00237	CcSEcCtD
Dextroamphetamine—Somnolence—Fluorouracil—skin cancer	0.00202	0.00236	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Temozolomide—skin cancer	0.00202	0.00235	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Dactinomycin—skin cancer	0.00201	0.00235	CcSEcCtD
Dextroamphetamine—Dyspepsia—Fluorouracil—skin cancer	0.002	0.00234	CcSEcCtD
Dextroamphetamine—Decreased appetite—Fluorouracil—skin cancer	0.00198	0.00231	CcSEcCtD
Dextroamphetamine—SLC18A2—female reproductive system—skin cancer	0.00197	0.0468	CbGeAlD
Dextroamphetamine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00196	0.00229	CcSEcCtD
Dextroamphetamine—Urticaria—Temozolomide—skin cancer	0.00196	0.00229	CcSEcCtD
Dextroamphetamine—Asthenia—Dactinomycin—skin cancer	0.00196	0.00228	CcSEcCtD
Dextroamphetamine—Body temperature increased—Temozolomide—skin cancer	0.00195	0.00228	CcSEcCtD
Dextroamphetamine—Abdominal pain—Temozolomide—skin cancer	0.00195	0.00228	CcSEcCtD
Dextroamphetamine—Diarrhoea—Dactinomycin—skin cancer	0.00187	0.00218	CcSEcCtD
Dextroamphetamine—Vomiting—Bleomycin—skin cancer	0.00186	0.00217	CcSEcCtD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—PTGER4—skin cancer	0.00185	0.0317	CbGpPWpGaD
Dextroamphetamine—Rash—Bleomycin—skin cancer	0.00184	0.00215	CcSEcCtD
Dextroamphetamine—Dermatitis—Bleomycin—skin cancer	0.00184	0.00215	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Temozolomide—skin cancer	0.00182	0.00212	CcSEcCtD
Dextroamphetamine—SLC6A3—Dopaminergic Neurogenesis—SHH—skin cancer	0.00181	0.031	CbGpPWpGaD
Dextroamphetamine—Urticaria—Fluorouracil—skin cancer	0.0018	0.00211	CcSEcCtD
Dextroamphetamine—Body temperature increased—Fluorouracil—skin cancer	0.0018	0.0021	CcSEcCtD
Dextroamphetamine—Palpitations—Docetaxel—skin cancer	0.00178	0.00207	CcSEcCtD
Dextroamphetamine—Asthenia—Temozolomide—skin cancer	0.00177	0.00207	CcSEcCtD
Dextroamphetamine—Convulsion—Docetaxel—skin cancer	0.00174	0.00203	CcSEcCtD
Dextroamphetamine—Nausea—Bleomycin—skin cancer	0.00174	0.00203	CcSEcCtD
Dextroamphetamine—Hypertension—Docetaxel—skin cancer	0.00173	0.00203	CcSEcCtD
Dextroamphetamine—Vomiting—Dactinomycin—skin cancer	0.00173	0.00202	CcSEcCtD
Dextroamphetamine—Rash—Dactinomycin—skin cancer	0.00172	0.00201	CcSEcCtD
Dextroamphetamine—Chest pain—Docetaxel—skin cancer	0.00171	0.002	CcSEcCtD
Dextroamphetamine—Diarrhoea—Temozolomide—skin cancer	0.00169	0.00197	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Fluorouracil—skin cancer	0.00167	0.00195	CcSEcCtD
Dextroamphetamine—Dry mouth—Docetaxel—skin cancer	0.00167	0.00195	CcSEcCtD
Dextroamphetamine—ADRA1B—head—skin cancer	0.00166	0.0394	CbGeAlD
Dextroamphetamine—SLC18A2—head—skin cancer	0.00165	0.0391	CbGeAlD
Dextroamphetamine—Anaphylactic shock—Docetaxel—skin cancer	0.00164	0.00191	CcSEcCtD
Dextroamphetamine—Dizziness—Temozolomide—skin cancer	0.00163	0.0019	CcSEcCtD
Dextroamphetamine—Infection—Docetaxel—skin cancer	0.00163	0.0019	CcSEcCtD
Dextroamphetamine—Nausea—Dactinomycin—skin cancer	0.00162	0.00189	CcSEcCtD
Dextroamphetamine—Tachycardia—Docetaxel—skin cancer	0.0016	0.00187	CcSEcCtD
Dextroamphetamine—Vomiting—Temozolomide—skin cancer	0.00157	0.00183	CcSEcCtD
Dextroamphetamine—Anorexia—Docetaxel—skin cancer	0.00156	0.00183	CcSEcCtD
Dextroamphetamine—Rash—Temozolomide—skin cancer	0.00155	0.00182	CcSEcCtD
Dextroamphetamine—Diarrhoea—Fluorouracil—skin cancer	0.00155	0.00182	CcSEcCtD
Dextroamphetamine—Dermatitis—Temozolomide—skin cancer	0.00155	0.00181	CcSEcCtD
Dextroamphetamine—Headache—Temozolomide—skin cancer	0.00154	0.0018	CcSEcCtD
Dextroamphetamine—ADRA1A—epithelium—skin cancer	0.00151	0.0357	CbGeAlD
Dextroamphetamine—Dizziness—Fluorouracil—skin cancer	0.0015	0.00175	CcSEcCtD
Dextroamphetamine—Insomnia—Docetaxel—skin cancer	0.00148	0.00173	CcSEcCtD
Dextroamphetamine—Nausea—Temozolomide—skin cancer	0.00146	0.00171	CcSEcCtD
Dextroamphetamine—Dyspnoea—Docetaxel—skin cancer	0.00146	0.00171	CcSEcCtD
Dextroamphetamine—Somnolence—Docetaxel—skin cancer	0.00146	0.0017	CcSEcCtD
Dextroamphetamine—Vomiting—Fluorouracil—skin cancer	0.00144	0.00169	CcSEcCtD
Dextroamphetamine—Dyspepsia—Docetaxel—skin cancer	0.00144	0.00169	CcSEcCtD
Dextroamphetamine—Rash—Fluorouracil—skin cancer	0.00143	0.00167	CcSEcCtD
Dextroamphetamine—Dermatitis—Fluorouracil—skin cancer	0.00143	0.00167	CcSEcCtD
Dextroamphetamine—Decreased appetite—Docetaxel—skin cancer	0.00143	0.00166	CcSEcCtD
Dextroamphetamine—Headache—Fluorouracil—skin cancer	0.00142	0.00166	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Docetaxel—skin cancer	0.00142	0.00165	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—PTCH2—skin cancer	0.00141	0.0242	CbGpPWpGaD
Dextroamphetamine—Fatigue—Docetaxel—skin cancer	0.00141	0.00165	CcSEcCtD
Dextroamphetamine—Constipation—Docetaxel—skin cancer	0.0014	0.00164	CcSEcCtD
Dextroamphetamine—Nausea—Fluorouracil—skin cancer	0.00135	0.00158	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00134	0.023	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal pain—Docetaxel—skin cancer	0.00134	0.00157	CcSEcCtD
Dextroamphetamine—Abdominal pain—Docetaxel—skin cancer	0.0013	0.00151	CcSEcCtD
Dextroamphetamine—Body temperature increased—Docetaxel—skin cancer	0.0013	0.00151	CcSEcCtD
Dextroamphetamine—SLC6A3—head—skin cancer	0.00125	0.0295	CbGeAlD
Dextroamphetamine—Hypersensitivity—Docetaxel—skin cancer	0.00121	0.00141	CcSEcCtD
Dextroamphetamine—SLC6A2—female reproductive system—skin cancer	0.0012	0.0285	CbGeAlD
Dextroamphetamine—Asthenia—Docetaxel—skin cancer	0.00118	0.00137	CcSEcCtD
Dextroamphetamine—ADRA1A—lymphoid tissue—skin cancer	0.00116	0.0275	CbGeAlD
Dextroamphetamine—SLC18A2—lymph node—skin cancer	0.00115	0.0274	CbGeAlD
Dextroamphetamine—Diarrhoea—Docetaxel—skin cancer	0.00112	0.00131	CcSEcCtD
Dextroamphetamine—Dizziness—Docetaxel—skin cancer	0.00108	0.00127	CcSEcCtD
Dextroamphetamine—Vomiting—Docetaxel—skin cancer	0.00104	0.00122	CcSEcCtD
Dextroamphetamine—Rash—Docetaxel—skin cancer	0.00103	0.00121	CcSEcCtD
Dextroamphetamine—Dermatitis—Docetaxel—skin cancer	0.00103	0.00121	CcSEcCtD
Dextroamphetamine—Headache—Docetaxel—skin cancer	0.00103	0.0012	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—MC1R—skin cancer	0.00102	0.0175	CbGpPWpGaD
Dextroamphetamine—SLC6A2—head—skin cancer	0.001	0.0238	CbGeAlD
Dextroamphetamine—Nausea—Docetaxel—skin cancer	0.000974	0.00114	CcSEcCtD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000936	0.016	CbGpPWpGaD
Dextroamphetamine—ADRA1A—head—skin cancer	0.000934	0.0222	CbGeAlD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000883	0.0151	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RHOU—skin cancer	0.000878	0.015	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—SHH—skin cancer	0.000729	0.0125	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PTCH2—skin cancer	0.000726	0.0124	CbGpPWpGaD
Dextroamphetamine—SLC6A2—lymph node—skin cancer	0.000704	0.0167	CbGeAlD
Dextroamphetamine—TAAR1—GPCR ligand binding—SMO—skin cancer	0.000691	0.0118	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—PTCH1—skin cancer	0.000691	0.0118	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—PTGER4—skin cancer	0.000673	0.0115	CbGpPWpGaD
Dextroamphetamine—CYP2D6—female reproductive system—skin cancer	0.000659	0.0156	CbGeAlD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00063	0.0108	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—MC1R—skin cancer	0.000578	0.00988	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000558	0.00954	CbGpPWpGaD
Dextroamphetamine—CYP2D6—head—skin cancer	0.00055	0.0131	CbGeAlD
Dextroamphetamine—TAAR1—Signaling by GPCR—MC1R—skin cancer	0.000525	0.00898	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000476	0.00813	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTCH2—skin cancer	0.000429	0.00733	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000397	0.00678	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—PTGER4—skin cancer	0.00038	0.0065	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—SHH—skin cancer	0.000374	0.0064	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—PTCH2—skin cancer	0.000358	0.00612	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PTCH1—skin cancer	0.000355	0.00606	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—SMO—skin cancer	0.000355	0.00606	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000352	0.00602	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PTGER4—skin cancer	0.000345	0.0059	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00034	0.00581	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—GLI2—skin cancer	0.000325	0.00556	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00032	0.00547	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—PTCH2—skin cancer	0.000318	0.00544	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MC1R—skin cancer	0.00031	0.0053	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—GLI1—skin cancer	0.000306	0.00523	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000302	0.00516	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SUFU—skin cancer	0.00029	0.00495	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—BRAF—skin cancer	0.000288	0.00492	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000284	0.00485	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000261	0.00446	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—MC1R—skin cancer	0.000259	0.00442	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000232	0.00396	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—MC1R—skin cancer	0.00023	0.00393	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000223	0.00382	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RHOU—skin cancer	0.000222	0.0038	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SHH—skin cancer	0.000221	0.00378	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—BRAF—skin cancer	0.00022	0.00377	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RASA1—skin cancer	0.00022	0.00375	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTCH1—skin cancer	0.000209	0.00358	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SMO—skin cancer	0.000209	0.00358	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTGER4—skin cancer	0.000204	0.00349	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000198	0.00339	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RHOU—skin cancer	0.000197	0.00337	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—SHH—skin cancer	0.000184	0.00315	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PTCH2—skin cancer	0.000184	0.00314	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—FOXO4—skin cancer	0.00018	0.00308	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—SMO—skin cancer	0.000175	0.00299	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—PTCH1—skin cancer	0.000175	0.00299	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—BRAF—skin cancer	0.000172	0.00293	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—HRAS—skin cancer	0.000171	0.00292	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—PTGER4—skin cancer	0.00017	0.00291	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—TP53—skin cancer	0.000168	0.00288	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—SHH—skin cancer	0.000164	0.0028	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PTCH2—skin cancer	0.000163	0.00279	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—PTCH1—skin cancer	0.000155	0.00265	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—SMO—skin cancer	0.000155	0.00265	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—PTGER4—skin cancer	0.000151	0.00258	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—TP53—skin cancer	0.000149	0.00256	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—MC1R—skin cancer	0.000146	0.0025	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—MC1R—skin cancer	0.000133	0.00227	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—skin cancer	0.000132	0.00226	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—BRAF—skin cancer	0.000131	0.00225	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—MC1R—skin cancer	0.00013	0.00222	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TERT—skin cancer	0.00012	0.00206	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—MC1R—skin cancer	0.000118	0.00202	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTCH2—skin cancer	0.000109	0.00186	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—NRAS—skin cancer	0.000101	0.00173	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—HRAS—skin cancer	0.000101	0.00173	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTCH2—skin cancer	9.64e-05	0.00165	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PTGER4—skin cancer	9.62e-05	0.00164	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—BRAF—skin cancer	9.53e-05	0.00163	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—SHH—skin cancer	9.46e-05	0.00162	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PTCH1—skin cancer	8.97e-05	0.00153	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—SMO—skin cancer	8.97e-05	0.00153	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	8.86e-05	0.00151	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PTGER4—skin cancer	8.73e-05	0.00149	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—KRAS—skin cancer	8.72e-05	0.00149	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PTGER4—skin cancer	8.54e-05	0.00146	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—SHH—skin cancer	8.4e-05	0.00144	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GLI2—skin cancer	8.22e-05	0.00141	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—SMO—skin cancer	7.97e-05	0.00136	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PTCH1—skin cancer	7.97e-05	0.00136	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—skin cancer	7.89e-05	0.00135	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	7.87e-05	0.00135	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MC1R—skin cancer	7.84e-05	0.00134	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PTGER4—skin cancer	7.76e-05	0.00133	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GLI1—skin cancer	7.73e-05	0.00132	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	7.63e-05	0.0013	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—HRAS—skin cancer	7.42e-05	0.00127	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SUFU—skin cancer	7.33e-05	0.00125	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GLI2—skin cancer	7.3e-05	0.00125	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL6—skin cancer	7.1e-05	0.00121	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MC1R—skin cancer	6.97e-05	0.00119	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GLI1—skin cancer	6.87e-05	0.00117	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	6.77e-05	0.00116	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PLIN2—skin cancer	6.56e-05	0.00112	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SUFU—skin cancer	6.51e-05	0.00111	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	6.48e-05	0.00111	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	6.2e-05	0.00106	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—HRAS—skin cancer	6.04e-05	0.00103	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NRAS—skin cancer	5.99e-05	0.00102	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	5.76e-05	0.000984	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SHH—skin cancer	5.59e-05	0.000956	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RASA1—skin cancer	5.55e-05	0.00095	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	5.51e-05	0.000942	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTCH1—skin cancer	5.3e-05	0.000906	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SMO—skin cancer	5.3e-05	0.000906	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CSPG4—skin cancer	5.29e-05	0.000904	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTGER4—skin cancer	5.16e-05	0.000882	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—KRAS—skin cancer	5.15e-05	0.000881	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SHH—skin cancer	4.97e-05	0.000849	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RASA1—skin cancer	4.93e-05	0.000844	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTCH1—skin cancer	4.71e-05	0.000805	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SMO—skin cancer	4.71e-05	0.000805	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTGER4—skin cancer	4.58e-05	0.000783	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TP53—skin cancer	4.58e-05	0.000783	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FOXO4—skin cancer	4.56e-05	0.000779	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HRAS—skin cancer	4.38e-05	0.000749	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL6—skin cancer	4.19e-05	0.000717	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FOXO4—skin cancer	4.05e-05	0.000692	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ENO2—skin cancer	3.6e-05	0.000615	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TERT—skin cancer	3.04e-05	0.00052	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TERT—skin cancer	2.7e-05	0.000462	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—NRAS—skin cancer	2.56e-05	0.000438	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—BRAF—skin cancer	2.41e-05	0.000412	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	2.28e-05	0.000389	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—KRAS—skin cancer	2.21e-05	0.000377	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—BRAF—skin cancer	2.14e-05	0.000366	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ERCC2—skin cancer	2.09e-05	0.000357	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	1.96e-05	0.000335	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HRAS—skin cancer	1.88e-05	0.000321	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL6—skin cancer	1.8e-05	0.000307	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	1.67e-05	0.000285	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL6—skin cancer	1.59e-05	0.000273	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NRAS—skin cancer	1.51e-05	0.000259	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NRAS—skin cancer	1.35e-05	0.00023	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KRAS—skin cancer	1.3e-05	0.000223	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTGS2—skin cancer	1.25e-05	0.000214	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TP53—skin cancer	1.16e-05	0.000198	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KRAS—skin cancer	1.16e-05	0.000198	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HRAS—skin cancer	1.11e-05	0.000189	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL6—skin cancer	1.06e-05	0.000181	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TP53—skin cancer	1.03e-05	0.000176	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HRAS—skin cancer	9.84e-06	0.000168	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL6—skin cancer	9.42e-06	0.000161	CbGpPWpGaD
